Metalloproteinases and tissue inhibitors of matrix-metalloproteinases in plasma of patients with prostate cancer and in prostate cancer tissue

Annals of the New York Academy of Sciences

Volumn 878, Issue , 1999, Pages 544-546

  Lein, Michael ^a   Nowak, Lars ^a   Jung, Klaus ^a   Laube, Christian ^a   Ulbricht, Norbert ^a   Schnorr, Dietmar ^a   Loening, Stefan A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

CONFERENCE PAPER; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROSTATE CANCER; PROSTATE HYPERTROPHY;

EID: 0032816036     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb07722.x     Document Type: Conference Paper

References (2)

1. 1. Murray, G.I. et al. 1996. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature 2: 461-462.
2. 2. Anderson, I.C. et al. 1995. Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. Cancer Res. 55: 4120-4126.